A trial of valganciclovir prophylaxis for cytomegalovirus prevention in lung transplant recipients.
about
Valganciclovir for cytomegalovirus prevention in solid organ transplant patients: an evidence-based reassessment of safety and efficacyMeta-Analysis and Potential Role of Preexisting Heterosubtypic Cellular Immunity Based on Variations in Disease Severity Outcomes for Influenza Live Viral Challenges in HumansAntiviral drug resistance of human cytomegalovirus.Recombinant phenotyping of cytomegalovirus UL97 kinase sequence variants for ganciclovir resistance.Primary response against cytomegalovirus during antiviral prophylaxis with valganciclovir, in solid organ transplant recipientsCytomegalovirus pneumonitis is a risk for bronchiolitis obliterans syndrome in lung transplantation.Phenotypic diversity of cytomegalovirus DNA polymerase gene variants observed after antiviral therapy.Preemptive therapy prevents cytomegalovirus end-organ disease in treatment-naïve patients with advanced HIV-1 infection in the HAART era.Incidence, Risk Factors and Outcomes of Delayed-onset Cytomegalovirus Disease in a Large Retrospective Cohort of Lung Transplant Recipients.Strategies for the prevention of infection after solid organ transplantation.Prophylactic and therapeutic adenoviral vector-based multivirus-specific T-cell immunotherapy for transplant patients.Ganciclovir-resistant cytomegalovirus infections among lung transplant recipients are associated with poor outcomes despite treatment with foscarnet-containing regimens.Strategies for managing cytomegalovirus in transplant recipients.Is prevention the best treatment? CMV after lung transplantation.Efficacy of valganciclovir and ganciclovir for cytomegalovirus disease in solid organ transplants: A meta-analysis.Risk factors, survival, and impact of prophylaxis length in cytomegalovirus-seropositive lung transplant recipients: A prospective, observational, multicenter study.Critical analysis of valganciclovir dosing and renal function on the development of cytomegalovirus infection in kidney transplantation.Cytomegalovirus disease in lung transplantation: impact of recipient seropositivity and duration of antiviral prophylaxis.Cytomegalovirus and long-term outcome after lung transplantation in Gothenburg, Sweden.Clinical impact of ganciclovir-resistant cytomegalovirus infections in solid organ transplant patients.Cytomegalovirus disease and infection in lung transplant recipients in the setting of planned indefinite valganciclovir prophylaxis.Low-Dose Valganciclovir for CMV Prophylaxis after Lung Transplantation
P2860
Q28475480-F7C00629-5931-4BCC-BBED-280E3BDAB29AQ30375769-CC890B73-B790-44D8-A519-3BDD15D81819Q30430427-DAA361BB-BC72-41F6-948F-085BAC7BA99EQ33876672-EA72A888-EC03-4BD5-BEE1-ABA93963751EQ33932079-8EDCDE71-FECA-4A70-A88C-DE949DE9F758Q33950112-9A7493BA-0F70-46E5-B42D-326FB6C1A60BQ34687313-71855591-81E6-489D-BF6D-55F1D15E3D6FQ34750093-5479200E-C0DD-456E-8162-AC2532463B54Q35946563-5079DF73-4D56-442E-8FBA-4B32F04BB2DEQ36670902-79A5D485-8C61-4892-948D-AE981FE6DD0EQ37203522-019F3D5D-52F2-4196-B78E-68DC4C566E7FQ37544353-3EFA5AE9-C679-4250-9901-4D307BC1A3CBQ37773992-9FCCA5F4-CFFC-4F88-BA89-67A3481EF1B1Q37954420-2A2E33E6-39D9-408A-958F-CC218893FDE6Q38364698-4FD946B8-EFD1-4098-B9C1-098290B77DFDQ40293836-076B4480-6DD3-459E-BAF6-09F01F7A0C8EQ42271698-E6D6E42D-347B-4445-9C88-0C83D8CB3D90Q42283057-49DBFC45-F33D-419F-938C-7EC1BF871826Q43191210-232DB7EC-B475-4407-A5EE-743F8702C100Q46877359-8C98B4A2-7565-4812-84C3-8E5966D68A93Q53651832-6981C988-396F-459B-9753-DF68DE6FEB3FQ58998329-74640B3D-C4E8-4E05-9A28-333D89AA2C63
P2860
A trial of valganciclovir prophylaxis for cytomegalovirus prevention in lung transplant recipients.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh-hant
name
A trial of valganciclovir prop ...... in lung transplant recipients.
@en
A trial of valganciclovir prop ...... in lung transplant recipients.
@nl
type
label
A trial of valganciclovir prop ...... in lung transplant recipients.
@en
A trial of valganciclovir prop ...... in lung transplant recipients.
@nl
prefLabel
A trial of valganciclovir prop ...... in lung transplant recipients.
@en
A trial of valganciclovir prop ...... in lung transplant recipients.
@nl
P2093
P2860
P1476
A trial of valganciclovir prop ...... in lung transplant recipients
@en
P2093
Atul Humar
Deepali Kumar
Guy Boivin
Jayne Fenton
Jutta Preiksaitis
Kathy Jackson
P2860
P304
P356
10.1111/J.1600-6143.2005.00866.X
P407
P577
2005-06-01T00:00:00Z